Opinions
Jim Cramer - Mad Money
Campbell Soup Company
CPB-N
DON'T BUY
May 30, 2025
$34.040
Stock price when the opinion was issued
food processing
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
COMMENT
When investors fear the pandemic and a Fed-induced slowdown, the more conservative ones buy consumer staples. Staples have been beaten up this year, but today they rallied. Campbell's is up 8% so far this month, despite last week's mixed quarter. Yesterday, they held an investor day and unveiled very bullish long-term growth targets. Could this be the start of a larger move?
food processing
Premium content
PAST TOP PICK
Premium content
PAST TOP PICK
(A Top Pick Nov 12/20, Down 12.4%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with CPB has triggered its stop at $42. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 12%, when combined with the previous buy recommendation.
food processing
BUY
He recommends packaged food stocks as safe havens if there's a recession. CPB is up 22% this year. They keep putting up good numbers and just reported a 14-cent earnings beat, higher than expected sales (15% organic growth vs. expected 10%), and they raised their full-year forecast. There's more room to run.
food processing
BUY
Up 31% this year so far. They've always had strong brands. They had supply chain problems this year, but thankfully are in the past. They raised prices to offset shortages and won't lower prices now that supplies problems have ended. Last week they reported a monster earnings beat, 15% organic sales growth and a strong forecast. Looks very good for 2023.
food processing
DON'T BUY
They just reported and today held their investors' call. They say that high prices are scaring away customers with spending starting to slow last January. There was weakenss in crackers and chips. Not helping are the new 50% tariffs on steel and aluminum, precisely what Campbell soup cans are made of. The company blames general economic weakness, but don't mention the GLP-1 drug. The latter makes sense, not general economic weakness. CPB pays a safe 4.5% dividend, but no, it isn't worth getting paid to wait, not with the weight-loss drugs still selling.
food processing
It reports Monday. Trades at 11x PE and pays a 4% dividend, but gross margins have been squeezed due to higher costs--from tariffs. Meanwhile, the weight-loss drugs make you feel full, another headwind.